No Data
Jiangsu Yahong Pharmaceutical Technology Co., Ltd. 2024 Annual Report
Summary of the 2024 Annual Report of Jiangsu Yahong Pharmaceutical Technology Co., Ltd.
Yahong Pharmaceuticals (688176.SH) released its performance for 2024, with a net loss attributable to the parent company of 0.384 billion yuan, narrowing the loss.
Yahong Pharmaceutical (688176.SH) released its annual report for 2024, with the company's revenue for the 2024 fiscal year being 2....
Yahong Pharmaceuticals: In 2024, revenue is expected to increase by 1365.55% year-on-year to 0.202 billion yuan as the launch process for innovative products accelerates.
On April 18, Glonghui reported that Yahong Pharmaceutical disclosed its annual report, showing that in 2024, the company achieved revenue of 0.202 billion yuan, a year-on-year increase of 1365.55%, demonstrating rapid growth and reaching the target of breakeven in commercial Operation. During the reporting period, the company's two commercialized products, Ouyoubi and Dipaite, covered 1,000 and over 500 target Hospitals respectively, with rapid sales growth, capturing 27% and 12% of the market shares of Neraltyn tablets and Pezolapine tablets. At the same time, the progress of launching the company's innovative products has accelerated: the drug for diagnosing and managing bladder cancer, APL-1706 (brand name: Haike.
Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.
In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
